Biogen and Eisai discontinue Alzheimer’s trials of BACE inhibitor
Biogen and Eisai have discontinued the clinical development programme of beta amyloid cleaving enzyme (BACE)...
Read More...
Focus:
-
![Ocrevus disease progression MS]()
Roche’s Ocrevus slows disease progression in two types of MS
Roche has announced Ocrevus (ocrelizumab) reduced the long-term risk of disability progression in patients with...
Read More...
-
![Orkambi available in Scotland]()
Scotland reaches access agreement with Vertex for CF drug Orkambi
Vertex Pharmaceuticals has announced two of its cystic fibrosis (CF) drugs, Orkambi (lumacaftor-ivacaftor) and Symkevi...
Read More...
-
![disruption to medicines no-deal Brexit]()
UK Government confirms disruption to medicines in event of no-deal Brexit
A document published by the UK Government laying out the worst case scenario if the...
Read More...
-
![gene therapy Genenta funding]()
Gene therapy biotech Genenta raises €13.2m in funding round
Milan-based clinical stage biotech Genenta Science has announced it has raised €13.2m at the closing...
Read More...
-
![EC Stelara ulcerative colitis]()
EC expands label of Janssen’s Stelara to include ulcerative colitis
Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab)...
Read More...
-
![Theragnostics radiopharmaceuticals PARPi]()
AZ licenses PARPi to Theragnostics to develop novel radiopharmaceuticals
UK-based clinical stage biotech Theragnostics has signed a licensing agreement with AstraZeneca (AZ) related to...
Read More...
-
![Achilles personalised cell therapies]()
Personalised cell therapy developer Achilles closes £100m round
UK-based Achilles Therapeutics has announced the closing of its £100m Series B financing round, which...
Read More...
-
![heart failure drug Entresto]()
Novartis’s heart failure drug Entresto presents mixed trial results
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan)...
Read More...
-
![HRT for menopause increases breast cancer risk]()
Study finds menopausal HRT drastically increases breast cancer risk
Research published in the Lancet has found that women taking hormone replacement therapy (HRT) to...
Read More...
Go Top
